InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain
InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
MLN | Ann: MLN undiluted NAV as at 26/3/19 - $0.9618 | 28/03/19 | 0 | 11 | |||
|
|||||||
MLN | Ann: MLN - Issue of Securities - 28 March 2019 | 28/03/19 | 0 | 10 | |||
|
|||||||
MLN | Ann: MLN – Notice of acquisition of Securities 27 March 2019 | 28/03/19 | 0 | 12 | |||
|
|||||||
MLN | Ann: MLN – Notice of acquisition of Securities 26 March 2019 | 27/03/19 | 0 | 19 | |||
|
|||||||
MLN | Ann: MLN – Notice of acquisition of Securities 22 March 2019 | 25/03/19 | 0 | 21 | |||
|
|||||||
MLN | Ann: MLN – Notice of acquisition of Securities 21 March 2019 | 22/03/19 | 0 | 26 | |||
|
|||||||
MLN | Ann: MLN undiluted NAV as at 19/3/19 - $0.9714 | 21/03/19 | 0 | 30 | |||
|
|||||||
MLN | Ann: DIVIDEND REINVESTMENT PLAN PRICE DETERMINED | 21/03/19 | 0 | 30 | |||
|
See All Discussions